School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China.
Int J Mol Sci. 2024 May 9;25(10):5151. doi: 10.3390/ijms25105151.
In our previous studies, a novel cryothermal therapy (CTT) was developed to induce systemic long-term anti-tumor immunity. Natural killer (NK) cells were found to play an important role in CTT-induced long-term immune-mediated tumor control at the late stage after CTT, but the underlying mechanism is unclear. Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that have potent immunosuppressive effects on T cells and weaken the long-term benefits of immunotherapy. Consequently, overcoming MDSC immunosuppression is essential for maintaining the long-term efficacy of immunotherapy. In this study, we revealed that NK cells considerably diminish MDSC accumulation at the late stage after CTT, boost T cell production, increase T cell activation, and promote MDSC maturation, culminating in Th1-dominant CD4 T cell differentiation and enhancing NK and CD8 T cell cytotoxicity. Additionally, NK cells activate ERK signaling in MDSCs through NKG2D-ligand interaction to increase the activity of tumor necrosis factor (TNF)-α converting enzyme (TACE)-cleaved membrane TNF-α. Furthermore, Increased TACE activity releases more soluble TNF-α from MDSCs to promote MDSC maturation. In our studies, we propose a novel mechanism by which NK cells can overcome MDSC-induced immunosuppression and maintain CTT-induced persistent anti-tumor immunity, providing a prospective therapeutic option to improve the performance of cancer immunotherapy.
在我们之前的研究中,开发了一种新型的冷冻治疗(CTT)来诱导全身性长期抗肿瘤免疫。研究发现自然杀伤(NK)细胞在 CTT 后晚期的长期免疫介导的肿瘤控制中发挥重要作用,但潜在机制尚不清楚。髓源抑制细胞(MDSCs)是不成熟的髓样细胞,对 T 细胞具有强大的免疫抑制作用,削弱了免疫疗法的长期益处。因此,克服 MDSC 的免疫抑制作用对于维持免疫疗法的长期疗效至关重要。在这项研究中,我们揭示了 NK 细胞在 CTT 后晚期显著减少 MDSC 的积累,增加 T 细胞的产生,增加 T 细胞的激活,并促进 MDSC 的成熟,最终导致 Th1 优势 CD4 T 细胞分化,并增强 NK 和 CD8 T 细胞的细胞毒性。此外,NK 细胞通过 NKG2D 配体相互作用激活 MDSC 中的 ERK 信号,增加肿瘤坏死因子(TNF)-α转化酶(TACE)切割的膜 TNF-α的活性。此外,增加的 TACE 活性从 MDSC 释放更多的可溶性 TNF-α,以促进 MDSC 的成熟。在我们的研究中,我们提出了一种新的机制,即 NK 细胞可以克服 MDSC 诱导的免疫抑制并维持 CTT 诱导的持续抗肿瘤免疫,为改善癌症免疫疗法的疗效提供了一种有前景的治疗选择。